查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592037

卡波西氏肉瘤市場：按類型、藥物類別、治療方法、治療方式 - 全球預測 2025-2030

Kaposi Sarcoma Market by Type (Classic Kaposi Sarcoma, Endemic Kaposi Sarcoma, Epidemic Kaposi Sarcoma), Drug Class (Doxil, Doxorubicin Hydrochloride Liposome, Intron A ), Treatment, Mode of Treatment - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年卡波西氏肉瘤市場價值為1.4029億美元，預計2024年將達到1.4555億美元，複合年成長率為3.73%，到2030年將達到1.814億美元。

卡波西氏肉瘤是一種在血管和淋巴管內壁形成的癌症，通常出現在皮膚和黏膜上。這個市場的需求和範圍集中在對先進診斷、有效治療方法和個人化治療的迫切需要，特別是考慮到免疫力缺乏的患者（例如愛滋病毒/愛滋病患者）的盛行率。最終用途市場包括醫院、研究機構和主要專注於腫瘤學和病毒學的專科診所。全球癌症發病率上升、分子生物學的進步以及對罕見疾病的認知和支持不斷增強，推動了市場成長。主要影響因素包括愛滋病毒的傳播、早期檢測方法的改進以及政府和非政府的支持措施。值得注意的是，生物技術公司和研究機構之間的合作為治療方法和藥物突破提供了有利可圖的機會。然而，挑戰包括高昂的研發成本、治療的潛在副作用以及擴大獲得全面醫療保健的機會的需要，特別是在新興市場。此外，一般人群對卡波西肉瘤的認知和理解有限，導致診斷較晚，並使治療挑戰複雜化。有前景的創新領域包括標靶治療、免疫治療以及將人工智慧整合到診斷中以提高早期檢測率。卡波西氏肉瘤相關皰疹病毒 (KSHV) 的研究為預防策略和新的治療方法提供了潛力。這個市場的性質是高度專業化的，需要腫瘤學家、病毒學家和藥理學家之間持續的多學科合作。捕捉市場機會的研究包括投資尖端研究、促進公私夥伴關係以及加強患者教育和推廣計劃，以確保早期診斷和遵守治療方法。儘管市場複雜，但改善全球患者治療效果的有效創新潛力巨大。

主要市場統計
基準年[2023] 1.4029億美元
預測年份 [2024] 1.4555億美元
預測年份 [2030] 1.814 億美元
複合年成長率（%） 3.73%

市場動態：快速發展的卡波西氏肉瘤市場的關鍵市場洞察

卡波西氏肉瘤市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 愛滋病毒相關疾病的盛行率增加 卡波西氏肉瘤
    • 接受器官移植的患者數量增加
    • 增加與卡波西氏肉瘤病相關的臨床研究
  • 市場限制因素
    • 卡波西氏肉瘤診斷治療高成本
  • 市場機會
    • 投資卡波西氏肉瘤治療的研發活動
    • 先進的高效抗逆轉濾病毒治療簡介
  • 市場挑戰
    • 缺乏技術純熟勞工和藥品供不應求

波特五力：駕馭卡波西氏肉瘤市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解卡波西氏肉瘤市場的外部影響

外部宏觀環境因素在塑造卡波西氏肉瘤市場表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解卡波西氏肉瘤市場的競爭格局

卡波西氏肉瘤市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣卡波西氏肉瘤市場供應商的績效評估

FPNV 定位矩陣是評估卡波西氏肉瘤市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製卡波西氏肉瘤市場的成功之路

卡波西氏肉瘤市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 與愛滋病毒相關的卡波西氏肉瘤盛行率不斷上升
      • 接受器官移植手術的患者數量增加
      • 增加與卡波西氏肉瘤病相關的臨床研究
    • 抑制因素
      • 卡波西氏肉瘤治療相關的高診斷成本
    • 機會
      • 投資與卡波西氏肉瘤治療相關的研發活動
      • 先進的高效抗逆轉濾病毒治療簡介
    • 任務
      • 缺乏熟練勞動力和藥物供不應求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章卡波西氏肉瘤市場：依類型

  • 經典（地中海）卡波西氏肉瘤
  • 地方性（非洲）卡波西氏肉瘤
  • 流行病（愛滋病相關）卡波西氏肉瘤
  • 醫源性（移植相關）卡波西氏肉瘤

第 7 章按藥物類別分類的卡波西氏肉瘤市場

  • Doxil（鹽酸阿黴素脂質體）
  • 鹽酸阿黴素脂質體
  • 內含子A（重組α干擾素-2b）
  • 紫杉醇
  • Pomalidomide
  • Pomalyst（Pomalidomide）
  • 重組α干擾素-2b
  • 硫酸長春鹼

第8章卡波西氏肉瘤治療市場

  • 生物療法
  • 化療
  • 冷凍療法
  • 心
  • 放射治療
  • 外科手術
  • 治療

第9章 卡波西氏肉瘤市場治療方法

  • 化療
  • 病灶內注射

第10章美洲卡波西氏肉瘤市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區卡波西氏肉瘤市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲卡波西氏肉瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aphios Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • John Wiley & Sons, Inc.
  • Johnson & Johnson Services, Inc
  • Lupin Ltd.
  • Merck & Co., Inc
  • Mylan NV
  • Navidea Biopharmaceuticals, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C994FA

The Kaposi Sarcoma Market was valued at USD 140.29 million in 2023, expected to reach USD 145.55 million in 2024, and is projected to grow at a CAGR of 3.73%, to USD 181.40 million by 2030.

Kaposi Sarcoma is a cancer that forms in the lining of blood and lymph vessels and typically appears on the skin or mucosal surfaces. The necessity and application scope in this market center around the urgent need for advanced diagnostics, effective therapeutics, and personalized treatments, especially given its prevalence among immunocompromised patients, such as those with HIV/AIDS. The end-use market predominantly includes hospitals, research institutes, and specialty clinics that focus on oncology and virology. Market growth is driven by the increasing global cancer burden, advancements in molecular biology, and the growing awareness and advocacy around rare diseases. Key influencing factors include the prevalence of HIV, improvements in early detection methods, and governmental and non-governmental support initiatives. Notably, collaborations between biotech companies and research institutions offer lucrative opportunities for breakthroughs in treatment modalities and drug discoveries. However, the market is challenged by the high costs of research and development, potential side effects of treatment, and a need for greater access to comprehensive healthcare, particularly in developing regions. Additionally, limited awareness and understanding of Kaposi Sarcoma in the general population contribute to late-stage diagnoses, compounding treatment challenges. Promising areas of innovation include targeted therapies, immunotherapies, and the integration of AI in diagnostics to improve early detection rates. Research on Kaposi Sarcoma-associated herpes virus (KSHV) offers potential for preventive strategies and novel therapeutic approaches. The nature of the market is highly specialized, requiring ongoing cross-disciplinary collaborations among oncologists, virologists, and pharmacologists. Recommendations for capturing market opportunities involve investing in cutting-edge research, fostering partnerships between public and private sectors, and enhancing patient education and outreach programs to ensure early diagnosis and adherence to treatment regimens. Despite the market complexities, there lies tremendous potential for impactful innovations that can improve patient outcomes globally.

KEY MARKET STATISTICS
Base Year [2023] USD 140.29 million
Estimated Year [2024] USD 145.55 million
Forecast Year [2030] USD 181.40 million
CAGR (%) 3.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Kaposi Sarcoma Market

The Kaposi Sarcoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of HIV-associated Kaposi Sarcoma
    • Rising number of patients undergoing organ transplantation procedures
    • Growing number of clinical studies related to Kaposi Sarcoma disease
  • Market Restraints
    • High cost associated with diagnosis of Kaposi Sarcoma treatment
  • Market Opportunities
    • Investment in R&D activities for Kaposi Sarcoma treatment
    • Introduction of advanced highly active antiretroviral treatment
  • Market Challenges
    • Lack of skilled workforce and shortage in the supply of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Kaposi Sarcoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Kaposi Sarcoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Kaposi Sarcoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Kaposi Sarcoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Kaposi Sarcoma Market

A detailed market share analysis in the Kaposi Sarcoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Kaposi Sarcoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Kaposi Sarcoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Kaposi Sarcoma Market

A strategic analysis of the Kaposi Sarcoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Kaposi Sarcoma Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals LLC, Aphios Corporation, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Getwell Oncology Pvt Ltd, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, John Wiley & Sons, Inc., Johnson & Johnson Services, Inc, Lupin Ltd., Merck & Co., Inc, Mylan N.V., Navidea Biopharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Kaposi Sarcoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Epidemic (AIDS-associated) Kaposi Sarcoma, and Iatrogenic (Transplant-Related) Kaposi Sarcoma.
  • Based on Drug Class, market is studied across Doxil (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Intron A (Recombinant Interferon Alfa-2b), Paclitaxel, Pomalidomide, Pomalyst (Pomalidomide), Recombinant Interferon Alfa-2b, and Vinblastine Sulfate.
  • Based on Treatment, market is studied across Biological Therapy, Chemotherapy, Cryosurgery, HAART, Radiation Therapy, Surgery, and Treatment.
  • Based on Mode of Treatment, market is studied across Chemotherapy and Intralesional Injection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of HIV-associated Kaposi Sarcoma
      • 5.1.1.2. Rising number of patients undergoing organ transplantation procedures
      • 5.1.1.3. Growing number of clinical studies related to Kaposi Sarcoma disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with diagnosis of Kaposi Sarcoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Investment in R&D activities for Kaposi Sarcoma treatment
      • 5.1.3.2. Introduction of advanced highly active antiretroviral treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled workforce and shortage in the supply of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Kaposi Sarcoma Market, by Type

  • 6.1. Introduction
  • 6.2. Classic (Mediterranean) Kaposi Sarcoma
  • 6.3. Endemic (African) Kaposi Sarcoma
  • 6.4. Epidemic (AIDS-associated) Kaposi Sarcoma
  • 6.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma

7. Kaposi Sarcoma Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Doxil (Doxorubicin Hydrochloride Liposome)
  • 7.3. Doxorubicin Hydrochloride Liposome
  • 7.4. Intron A (Recombinant Interferon Alfa-2b)
  • 7.5. Paclitaxel
  • 7.6. Pomalidomide
  • 7.7. Pomalyst (Pomalidomide)
  • 7.8. Recombinant Interferon Alfa-2b
  • 7.9. Vinblastine Sulfate

8. Kaposi Sarcoma Market, by Treatment

  • 8.1. Introduction
  • 8.2. Biological Therapy
  • 8.3. Chemotherapy
  • 8.4. Cryosurgery
  • 8.5. HAART
  • 8.6. Radiation Therapy
  • 8.7. Surgery
  • 8.8. Treatment

9. Kaposi Sarcoma Market, by Mode of Treatment

  • 9.1. Introduction
  • 9.2. Chemotherapy
  • 9.3. Intralesional Injection

10. Americas Kaposi Sarcoma Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Kaposi Sarcoma Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Kaposi Sarcoma Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amneal Pharmaceuticals LLC
  • 4. Aphios Corporation
  • 5. Aurobindo Pharma Limited
  • 6. Bausch Health Companies Inc.
  • 7. Baxter International, Inc.
  • 8. Bayer AG
  • 9. Bristol-Myers Squibb Company
  • 10. Celgene Corporation
  • 11. Cipla Limited
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Getwell Oncology Pvt Ltd
  • 15. GlaxoSmithKline PLC
  • 16. Hikma Pharmaceuticals PLC
  • 17. John Wiley & Sons, Inc.
  • 18. Johnson & Johnson Services, Inc
  • 19. Lupin Ltd.
  • 20. Merck & Co., Inc
  • 21. Mylan N.V.
  • 22. Navidea Biopharmaceuticals, Inc.
  • 23. Pfizer Inc.
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. KAPOSI SARCOMA MARKET RESEARCH PROCESS
  • FIGURE 2. KAPOSI SARCOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. KAPOSI SARCOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. KAPOSI SARCOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC (MEDITERRANEAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC (AFRICAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC (AIDS-ASSOCIATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC (TRANSPLANT-RELATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXIL (DOXORUBICIN HYDROCHLORIDE LIPOSOME), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRON A (RECOMBINANT INTERFERON ALFA-2B), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALYST (POMALIDOMIDE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RECOMBINANT INTERFERON ALFA-2B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VINBLASTINE SULFATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BIOLOGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HAART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRALESIONAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 200. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 201. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023